Literature DB >> 7759307

Genetic susceptibility to multiple sclerosis in a Shanghai Chinese population. The role of the HLA class II genes.

M A Kelly1, Y Zhang, M A Penny, K H Jacobs, D A Cavan, C H Mijovic, K Y Chou, A H Barnett, D A Francis.   

Abstract

The association of MS with the HLA class II loci DR and DQ was investigated in subjects of Shanghai Chinese and British Caucasian origin. Our aim was to determine whether common alleles predispose to the disease in both races. In the Caucasian population MS was significantly positively associated with the putative haplotype DRB1*1501, DQA1*0102, DQB1*0602. In contrast, HLA class II alleles were not found to predispose to the disease in the Shanghai Chinese, suggesting that this haplotype is unlikely to be a universal susceptibility determinant. The absence of a disease association with the HLA-DR and -DQ genes in the Chinese population has a number of possible explanations. Our study suggests that other genetic and/or environmental components may be more important in determining susceptibility to MS in this race.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759307     DOI: 10.1016/0198-8859(94)00094-7

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  2 in total

1.  HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain).

Authors:  Oscar Fernández; Alfredo R-Antigüedad; María Jesús Pinto-Medel; Mari Mar Mendibe; Nestor Acosta; Begoña Oliver; Miguel Guerrero; Marcos Papais-Alvarenga; Victoria Fernández-Sánchez; Laura Leyva
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

2.  Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis.

Authors:  Mojdeh Ghabaee; Asghar Bayati; Shahla Amri Saroukolaei; Mohamad Ali Sahraian; Mohammad Hosein Sanaati; Parisa Karimi; Massoud Houshmand; Homa Sadeghian; Leila Hashemi Chelavi
Journal:  Cell Mol Neurobiol       Date:  2008-08-26       Impact factor: 5.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.